Disclaimer

Date of Last Revision: 9/14/2022

1. BINDING EFFECT. This is a binding agreement. By providing eligibility biographical information for yourself on our Internet site located at www.nethertonsyndromeclinicaltrials.com (the “Site”), you agree to abide by these Terms of Service and Use (“Terms”), as they may be amended by Therapeutics, Inc. (“Therapeutics”) from time to time in its sole discretion. Therapeutics will post a notice on the Site any time these Terms have been changed or otherwise updated. It is your responsibility to review these Terms periodically, and if at any time you find these Terms unacceptable, you must immediately leave the Site and cease all use of the Site.

YOU AGREE THAT BY USING THE SITE AND PROVIDING YOUR ELIGIBILITY INFORMATION YOU ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD, AND AGREE TO BE BOUND BY THE FOLLOWING TERMS. ONLY PERSONS OF LEGAL AGE CAN ACCEPT THESE TERMS AND SUBMIT ELIGIBILITY INFORMATION FOR PARTICIPATION IN THE STUDY CONDUCTED BY THERAPEUTICS. IF YOU VIOLATE ANY PORTION OF THIS PROVISION, THERAPEUTICS WILL IMMEDIATELY CANCEL YOUR RIGHT TO USE THE SITE AND PARTICIPATE IN ITS STUDY.

2. PRIVACY POLICY. Therapeutics respects your privacy and permits you to control the treatment of your personal information. A complete statement of Therapeutics’ current privacy policy can be found by clicking here. Therapeutics’ privacy policy is expressly incorporated into these Terms by this reference.

3. STUDY. Therapeutics is evaluating the safety and effectiveness of a topical investigational drug for people with Netherton Syndrome (NS) (“Study”). If you are chosen to participate in the Study, Therapeutics will provide you with Study information and disclosures as required under applicable FDA regulations. As part of the recruitment efforts for the Study, Therapeutics is publishing the Site to collect eligibility information for participants in the Study (“Participants”).

4. CLINICAL INVESTIGATOR. The name and addresses of the clinical investigators for the Study can be found here. If you have specific questions about the Study, you can contact the Project Manager at: pm.nethertonsyndrome@therapeuticsinc.com.

5. STUDY PURPOSE. The purpose of the Study is to investigate the effectiveness of the investigational drug for the indication of Netherton Syndrome and to monitor and measure side effects.

6. PARTICIPANTS. Participants may be male or female, 14 years of age or older and must be diagnosed with Netherton Syndrome. Female participants may not be pregnant, lactating or planning to become pregnant.

7. PARTICIPANT BENEFITS. Participants in the Study will receive no cost study-related skin examinations by a Board Certified Study Doctor, supplies of the study drug at no cost, and reimbursement for any time and travel involved with examinations and other study visits, as more fully detailed in the study information and disclosures.

8. PROVIDING ELIGIBILITY INFORMATION. In order to determine your eligibility for the study, we require that you take a brief survey about your NS medications. In order to be able to provide eligibility information, you must complete the registration process by providing the complete and accurate information requested on the registration form, including your full name and email address, confirm that you are over the age of 18 and accept these Terms. For participants 14-17 years of age, parental/legal guardian consent is required to accept these Terms. You are entirely responsible for maintaining the confidentiality of your Site credentials. You may not use the identity or Site credentials of someone else at any time. You agree to notify Therapeutics immediately of any unauthorized use of your Site credentials. You may be held liable for any false eligibility information you provide on the Site.